GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (FRA:8640) » Definitions » Shiller PE Ratio

Lixte Biotechnology Holdings (FRA:8640) Shiller PE Ratio : (As of Apr. 28, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lixte Biotechnology Holdings Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Lixte Biotechnology Holdings Shiller PE Ratio Historical Data

The historical data trend for Lixte Biotechnology Holdings's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Shiller PE Ratio Chart

Lixte Biotechnology Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lixte Biotechnology Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lixte Biotechnology Holdings's Shiller PE Ratio

For the Biotechnology subindustry, Lixte Biotechnology Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lixte Biotechnology Holdings's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lixte Biotechnology Holdings's Shiller PE Ratio falls into.



Lixte Biotechnology Holdings Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Lixte Biotechnology Holdings's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Lixte Biotechnology Holdings's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/129.4194*129.4194
=0.000

Current CPI (Dec. 2023) = 129.4194.

Lixte Biotechnology Holdings Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.868 99.695 -1.127
201406 -0.883 100.560 -1.136
201409 -0.466 100.428 -0.601
201412 -0.487 99.070 -0.636
201503 -1.109 99.621 -1.441
201506 -0.535 100.684 -0.688
201509 -1.069 100.392 -1.378
201512 -0.551 99.792 -0.715
201603 -0.539 100.470 -0.694
201606 -0.534 101.688 -0.680
201609 -0.535 101.861 -0.680
201612 -0.569 101.863 -0.723
201703 -0.561 102.862 -0.706
201706 -0.534 103.349 -0.669
201709 -0.503 104.136 -0.625
201712 -0.507 104.011 -0.631
201803 -0.487 105.290 -0.599
201806 -0.514 106.317 -0.626
201809 -1.028 106.507 -1.249
201812 -0.527 105.998 -0.643
201903 -0.531 107.251 -0.641
201906 -0.531 108.070 -0.636
201909 -1.090 108.329 -1.302
201912 -0.360 108.420 -0.430
202003 -0.271 108.902 -0.322
202006 -0.266 108.767 -0.317
202009 -1.189 109.815 -1.401
202012 -0.658 109.897 -0.775
202103 -1.176 111.754 -1.362
202106 -1.079 114.631 -1.218
202109 -0.765 115.734 -0.855
202112 -1.328 117.630 -1.461
202203 -1.090 121.301 -1.163
202206 -0.899 125.017 -0.931
202209 -0.899 125.227 -0.929
202212 -0.935 125.222 -0.966
202303 -0.747 127.348 -0.759
202306 -0.923 128.729 -0.928
202309 -0.459 129.860 -0.457
202312 0.000 129.419 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lixte Biotechnology Holdings  (FRA:8640) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Lixte Biotechnology Holdings Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lixte Biotechnology Holdings (FRA:8640) Business Description

Traded in Other Exchanges
Address
680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.

Lixte Biotechnology Holdings (FRA:8640) Headlines

No Headlines